The spread of the COVID-19 pandemic has caused us to reconsider how we treat our patients with multiple sclerosis (MS) and even the role of immunosuppression in autoimmunity. How do we decide what the best course of action is, and what does limited research available tell us about making the right treatment decision? Those are the exact questions Dr. Paul Doghramji explores with Dr. Amit Bar-Or.